Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Supernus Pharmaceuticals's average diluted shares outstanding for the quarter that ended in Jun. 2026 was 58.1 Mil.
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Supernus Pharmaceuticals Shares Outstanding (Diluted Average) Related Terms
Supernus Pharmaceuticals Shares Outstanding (Diluted Average) Historical Data
* Premium members only.
The historical data trend for Supernus Pharmaceuticals's Shares Outstanding (Diluted Average) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
What does a Shares Outstanding (Diluted Average) of 58.1 Mil mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Shares Outstanding (Diluted Average) of 58.1 Mil as of Jun. 2026. The average shares outstanding over two periods including dilutive securities like preferred shares and convertibles. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) too high?
Supernus Pharmaceuticals' current Shares Outstanding (Diluted Average) is 58.1 Mil. Overall, Supernus Pharmaceuticals has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) compare to RGC and BCRX?
Supernus Pharmaceuticals' Shares Outstanding (Diluted Average) of 58.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Diluted Average) for a Drug Manufacturers company?
A good Shares Outstanding (Diluted Average) depends on the Drug Manufacturers industry context. However, Shares Outstanding (Diluted Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Diluted Average) mean?
A high Shares Outstanding (Diluted Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods including dilutive securities like preferred shares and convertibles. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Shares Outstanding (Diluted Average) is 58.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Fairly Valued. The stock's GF Value™ is $43.68, compared to a current price of $47.03 — trading 7.7% above its estimated fair value. The current Shares Outstanding (Diluted Average) is 58.1 Mil. Supernus Pharmaceuticals' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Diluted Average) calculated?
Shares Outstanding (Diluted Average) is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Shares Outstanding (Diluted Average) is 58.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $47.03 is trading 7.7% above its estimated GF Value™ of $43.68.
GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0LB2:
Shares Outstanding (Diluted Average): 58.1 Mil
GF Value™: $43.68 vs. price of $47.03 (7.7% above fair value)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
78GF Score
Get the complete analysis for LTS:0LB2
Shares Outstanding (Diluted Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
